R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Mmemme COVID-19
COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe. COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA) VIREX (nchọpụta nchọpụta) N'ụlọ nyocha 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU 82%* Ọnwụnwa dị mkpa na Brazil                           OVYDSO (Olgotrelvir) Ọrịa mgbochi (Oral pill) 40%* Omicron mRNA ogwu Vaccine 20%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
immunotherapy
FUJOVEE (Abivertinib) NSCLC 82%* FUJOVEE (Abivertinib) B cell Lymphomas 60.2%* FUJOVEE (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* SCLC 82%* * Na mmekorita ya na Lee's Pharm na China PD-L1 (STI-3031)** Ọrịa Cervical 82%* ** Na US yana mmekorita ya na ImmuneOncia na Korea CD47 Tumor siri ike 40%* CD38 DAR-T multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal 40%* TROP2 ADC* Tumor siri ike 40%* Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor 40%* Ọnụ ego nke BCMA ADC Tumor Liquid 20%* Bevacizumab-ADNAB™ Ọrịa kansa Endometrial 40%* Na mmekorita ya na Mayo Clinic Bevacizumab-ADNAB™ Ọrịa Ovarian 40%* Na mmekorita ya na Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Na mmekorita ya na Mayo Clinic Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma 40%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Pain
ZTlido® 1.8% Neuralgia Postherpetic - PHN 99.8%* Gloperba® Ọgwụgwọ gout (Oral) 99.8%* SEMEXA (SP-102) Lumbar Radicular/Sciatica mgbu 82%* SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu 60.2%* SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia 20%* RTX (resiferatoxin) Epidural injection Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu 60.3%* Nhọpụta nwa mgbei RTX (resiferatoxin) Ụzọ intra-articular OA Mgbu OA Na-agafeghị agafe ruo Dị Ike 60.2%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Nnyefe ọgwụ Lymphatic
Sofusa® mgbochi TNF Autoimmune (RA) 40%* Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma 40%* Sofusa® mgbochi CTLA-4 Melanoma 40%* Na mmekorita ya na Mayo Clinic

Mmemme COVID-19
Mmemme igodo (Ngosipụta)	adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA COVIMARK™ (nchọpụta nchọpụta) FDA EUA VIREX (nchọpụta nchọpụta) PH III FUJOVEE (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA ogwu Mgbochi

immunotherapy
Mmemme igodo (Ngosipụta)	adọ
FUJOVEE (Abivertinib) Ph III FUJOVEE (Abivertinib) Ph II FUJOVEE (Abivertinib) Mgbochi PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 Tumor siri ike Ph I CD38 DAR-T (Otu Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I TROP2 ADC* Tumor siri ike Ph I Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I

Pain
Mmemme igodo (Ngosipụta)	adọ
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA Gloperba® 1.8% Ọgwụgwọ gout (Oral) Nkwado FDA SEMEXA (SP-102) Ph III SP-103 (Sistemụ Topical Lidocaine 5.4%) Ph II SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi RTX (resiferatoxin) Epidural injection Ph II RTX (resiferatoxin) Ụzọ intra-articular Ph II

Nnyefe Lymphatic
Mmemme igodo (Ngosipụta)	Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I Sofusa® mgbochi CTLA-4 (Melanoma) Ph I